RxDoctor Payments DataLook up a doctor →

John Wedlake, MD

Neurology · Stillwater, OKNPI 1215221478

Payments from drug & device makers

$17,170in general payments, 2019–2025

Across 1,064 payments — averaging $16.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$2K
  • AbbVie$2K
  • Acadia Pharmaceuticals Inc$1K
  • SK Life Science, Inc.$1K
  • UCB, Inc.$989
  • Merz Pharmaceuticals, LLC$613
  • plus $9K from 48 others

What the payments were for

  • Speaking & faculty fees$360%
  • Food & beverage$16,97099%
  • Education$1651%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,170 in reported general payments places this provider in the 70th percentile of 152 neurology providers in Oklahoma.

See all neurology providers in Oklahoma

Medicare billing

Part B allowed, 2024
$337,273
Medicare patients
670
Services billed
3,082

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PanzygaImmun Glob G(Igg)-Ifas/Glycine16$327,903
Gamunex-CImmune Globul G/Gly/Iga Avg 4615$126,106
MayzentSiponimod12$124,056
Kesimpta PenOfatumumab11$109,974
NuplazidPimavanserin Tartrate12$59,703
GlatopaGlatiramer Acetate14$37,632
XcopriCenobamate29$34,696
QuliptaAtogepant22$23,558
EliquisApixaban29$23,155
Aimovig AutoinjectorErenumab-Aooe28$20,660
Emgality PenGalcanezumab-Gnlm13$8,967
XareltoRivaroxaban11$8,038
Memantine Hcl137$6,188
Donepezil Hcl291$4,044
Gabapentin226$3,709

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerPanzyga, Eliquis$540$351,05845 claims
Grifols USA, LLCGamunex-C$14$126,10615 claims
NovartisMayzent$1,942$124,05612 claims
Acadia Pharmaceuticals IncNuplazid$1,318$59,70312 claims
SK Life Science, Inc.Xcopri$1,036$34,69629 claims
AbbVieQulipta$1,821$23,55822 claims
Johnson & JohnsonXarelto$97$8,03811 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$294$77521 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 152 neurology providers in Oklahoma.

Other neurology in Stillwater

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →